Growth Inhibition of Malignant Melanoma by Intermediate Frequency Alternating Electric Fields,and the Underlying Mechanisms

Abstract

OBJECTIVE: This study investigated the antitumour effects of intermediate frequency alternating electric fields (IF-AEF) in a murine melanoma cell line (B16F10) and a mouse tumour model. METHODS: IF-AEF was applied at 100 kHz. Proliferation of B16F10 cells in vitro was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. IF-AEF was applied in vivo to mice bearing B16F10 tumours. Terminal deoxy-nucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay for apoptosis, and immunohistochemical detection of CD34 and vascular endothelial growth factor (VEGF), were performed. RESULTS: IF-AEF inhibited the proliferation of B16F10 cells in an electrical intensity and time-dependent manner. Treatment with IF-AEF for 7 days significantly inhibited the growth of tumours compared with untreated controls. IF-AEF induced apoptosis in vivo and reduced CD34-positive cell numbers; CD34 is a special marker of microvessel density. CONCLUSION: IF-AEF reduced microvessel density related to tumour growth and may serve as a therapeutic strategy for cancer treatment.

Keywords

Intermediate frequency Alternating electric field Melanoma Apoptosis Angiogenesis CD34 Vascular endothelial growth factor (VEGF)

References

Kirson

Dbalý

Tovarys

: Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA 2007; 104: 10152–10157.

Garon

Sawcer

Vernier

: In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies. Int J Cancer 2007; 121: 675–682.

Zhu

Liu

Dipolar molecules as impellers achieving electric-field-stimulated release. J Am Chem Soc 2010; 132: 1450–1451.

Odell

Jr Sorgnard

: Anti-inflammatory effects of electronic signal treatment. Pain Physician 2008; 11: 891–907.

Kirson

Gurvich

Schneiderman

: Disruption of cancer cell replication by alternating electric fields. Cancer Res 2004; 64: 3288–3295.

Elson

: Biologic effects of radiofrequency and microwave fields: in vivo and in vitro experimental results. In: Bronzino

(ed). The Biomedical Engineering Handbook. Boca Raton, FL: CRC Press, 1995; pp 1417–1423.

Salzberg

Kirson

Palti

: A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie 2008; 31: 362–365.

Kirson

Giladi

Gurvich

: Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis 2009; 26: 633–640.

Brem

Folkman

: Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 1976; 36: 2807–2812.

10.

Luo

Sun

: An experimental study of energy controllable steep pulse in the treatment of rat with subcutaneous transplantive tumor. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2007; 24: 492–495 [in Chinese, English abstract].

11.

Sauer

Bekhite

Hescheler

: Redox control of angiogenic factors and CD31-positive vessel-like structures in mouse embryonic stem cells after direct current electrical field stimulation. Exp Cell Res 2005; 304: 380–390.

12.

Traweek

Kandalaft

Mehta

: The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am J Clin Pathol 1991; 96: 25–31.

13.

Ferrara

Gerber

LeCouter

: The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676.

14.

McMahon

: VEGF receptor signaling in tumor angiogenesis. Oncologist 2000; 5 (suppl 1): 3–10.

15.

Bates

Heald

Curry

: Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways. J Physiol 2001; 533: 263–272.

16.

Garbe

Eigentler

Keilholz

: Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16: 5–24.

17.

Denekamp

: The tumour microcirculation as a target in cancer therapy: A clearer perspective. Eur J Clin Invest 1999; 29: 733–736.

18.

Sridhar

Shepherd

: Targeting angiogenesis: A review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003; 42 (suppl 1): S81–S91.

19.

Eskens

: Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004; 90: 1–7.

20.

Tozer

Kanthou

Baguley

: Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423–435.

21.

Siemann

Bibby

Dark

: Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005; 11: 416–420.

22.

Marmé

: The impact of anti-angiogenic agents on cancer therapy. J Cancer Res Clin Oncol 2003; 129: 607–620.

23.

Folkman

: The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65–71.

24.

Ellis

Liu

Ahmad

: Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol 2001; 28 (5 suppl 16): 94–104.

25.

Wedge

Ogilvie

Dukes

: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645–4655.

26.

Yano

Muguruma

Matsumori

: Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell—depleted severe combined immunodeficient mice. Clin Cancer Res 2005; 11: 8789–8798.

27.

Tozer

Prise

Wilson

: Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61: 6413–6422.